Moleculin Biotech, Inc. ( MBRX ) shares are trading higher on Wednesday after the company announced the online publication of preclinical data for its Annamycin Venetoclax Resistant AML model. What To Know: The preclinical data suggests that Annamycin effectively targets acute myeloid leukemia (AML) cell lines resistant to Cytarabine (Ara-C) and Venetoclax (VEN) in lab tests using cells from patients...

01:30 PM EST, 12/11/2024 (MT Newswires) -- Consumer stocks were mixed Wednesday afternoon with the Consumer Staples Select Sector SPDR Fund (XLP) fractionally lower and the Consumer Discretionary Select Sector SPDR Fund (XLY) rising 1.6%. In corporate news, Albertsons ( ACI ) terminated its planned $25 billion acquisition by Kroger ( KR ) after two courts ruled to block the...

01:33 PM EST, 12/11/2024 (MT Newswires) -- Comcast ( CMCSA ) subsidiary Comcast Business said Wednesday it has agreed to acquire Nitel, a Chicago-based connectivity services provider, from private equity firm Cinven. Financial details weren't disclosed. Nitel provides network-as-a-service and managed solutions to 6,600 US enterprise customers in financial services, healthcare, and education industries. Price: 39.70, Change: +0.17, Percent Change:...

01:33 PM EST, 12/11/2024 (MT Newswires) -- Moleculin Biotech's ( MBRX ) shares were up nearly 9% in recent Wednesday trading after the company announced preclinical data showcasing its drug candidate Annamycin's efficacy against venetoclax-resistant acute myeloid leukemia, or AML, cell lines. Presented at the American Society of Hematology's Annual Meeting, the study showed that Annamycin effectively targets Cytarabine, or...